Policymakers must work with insurers and GLP-1 manufacturers to make sure these life-changing therapies remain accessible. Blanket denials of coverage will harm patients, invite long-term costs, and worsen the stigma we should be fighting against.
obesity
Posted inOpinion
Healey’s veto of funding for GLP-1 drugs harms public employees and the economy
Shouldn’t Massachusetts lead the way, rather than leave its citizens behind on this critical issue?
